Material benefits:
1. Approval of Eisai's drug (more convincing than Aduhelm) will catalyse further investment in clinical research for Alzheimer's and other forms of dementia = benefit for CGS's clinical trials business.
2. Approval of Eisai's drug will generate a heightened need for cognitive assessment for diagnosis and ongoing monitoring of patients on drug = huge uplift for CGS's healthcare business.
What the hell just happened?, page-18
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.015(1.28%) |
Mkt cap ! $198.1M | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.16 | $61.70K | 53.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31512 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| CGS (ASX) Chart |